×
S&P 500   3,808.11 (-0.35%)
DOW   30,952.68 (+0.02%)
QQQ   282.69 (-0.30%)
AAPL   139.20 (+1.28%)
MSFT   259.47 (+1.17%)
META   162.62 (+1.21%)
GOOGL   2,224.50 (-0.70%)
AMZN   108.37 (+0.90%)
TSLA   669.15 (-4.13%)
NVDA   153.66 (-3.85%)
NIO   21.60 (-3.40%)
BABA   115.63 (-0.97%)
AMD   76.82 (-4.90%)
MU   55.56 (-3.98%)
CGC   3.50 (-3.05%)
T   20.86 (+1.21%)
GE   63.86 (-3.07%)
F   11.45 (-3.05%)
DIS   94.93 (-1.03%)
AMC   13.38 (-0.15%)
PFE   50.98 (+0.63%)
PYPL   70.94 (-1.23%)
NFLX   176.15 (-1.92%)
S&P 500   3,808.11 (-0.35%)
DOW   30,952.68 (+0.02%)
QQQ   282.69 (-0.30%)
AAPL   139.20 (+1.28%)
MSFT   259.47 (+1.17%)
META   162.62 (+1.21%)
GOOGL   2,224.50 (-0.70%)
AMZN   108.37 (+0.90%)
TSLA   669.15 (-4.13%)
NVDA   153.66 (-3.85%)
NIO   21.60 (-3.40%)
BABA   115.63 (-0.97%)
AMD   76.82 (-4.90%)
MU   55.56 (-3.98%)
CGC   3.50 (-3.05%)
T   20.86 (+1.21%)
GE   63.86 (-3.07%)
F   11.45 (-3.05%)
DIS   94.93 (-1.03%)
AMC   13.38 (-0.15%)
PFE   50.98 (+0.63%)
PYPL   70.94 (-1.23%)
NFLX   176.15 (-1.92%)
S&P 500   3,808.11 (-0.35%)
DOW   30,952.68 (+0.02%)
QQQ   282.69 (-0.30%)
AAPL   139.20 (+1.28%)
MSFT   259.47 (+1.17%)
META   162.62 (+1.21%)
GOOGL   2,224.50 (-0.70%)
AMZN   108.37 (+0.90%)
TSLA   669.15 (-4.13%)
NVDA   153.66 (-3.85%)
NIO   21.60 (-3.40%)
BABA   115.63 (-0.97%)
AMD   76.82 (-4.90%)
MU   55.56 (-3.98%)
CGC   3.50 (-3.05%)
T   20.86 (+1.21%)
GE   63.86 (-3.07%)
F   11.45 (-3.05%)
DIS   94.93 (-1.03%)
AMC   13.38 (-0.15%)
PFE   50.98 (+0.63%)
PYPL   70.94 (-1.23%)
NFLX   176.15 (-1.92%)
S&P 500   3,808.11 (-0.35%)
DOW   30,952.68 (+0.02%)
QQQ   282.69 (-0.30%)
AAPL   139.20 (+1.28%)
MSFT   259.47 (+1.17%)
META   162.62 (+1.21%)
GOOGL   2,224.50 (-0.70%)
AMZN   108.37 (+0.90%)
TSLA   669.15 (-4.13%)
NVDA   153.66 (-3.85%)
NIO   21.60 (-3.40%)
BABA   115.63 (-0.97%)
AMD   76.82 (-4.90%)
MU   55.56 (-3.98%)
CGC   3.50 (-3.05%)
T   20.86 (+1.21%)
GE   63.86 (-3.07%)
F   11.45 (-3.05%)
DIS   94.93 (-1.03%)
AMC   13.38 (-0.15%)
PFE   50.98 (+0.63%)
PYPL   70.94 (-1.23%)
NFLX   176.15 (-1.92%)
NASDAQ:EYES

Second Sight Medical Products Stock Forecast, Price & News

$2.08
-0.06 (-2.80%)
(As of 06/29/2022 12:24 PM ET)
Add
Compare
Today's Range
$2.06
$2.13
50-Day Range
$1.22
$2.57
52-Week Range
$1.14
$5.28
Volume
1,983 shs
Average Volume
456,532 shs
Market Capitalization
$81.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive EYES Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Second Sight Medical Products and its competitors with MarketBeat's FREE daily newsletter.

EYES Stock Forecast (MarketRank)

Overall MarketRank

1.52 out of 5 stars

Medical Sector

1042nd out of 1,433 stocks

Electromedical Equipment Industry

21st out of 30 stocks

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
Second Sight Medical Products logo

About Second Sight Medical Products (NASDAQ:EYES)

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.

EYES Stock News Headlines

EYES Stock Pops on Biotech Merger Plans. 5 Things to Know.
See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EYES
Employees
15
Year Founded
N/A

Company Calendar

Last Earnings
6/29/2020
Today
6/29/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$-8.92 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.38 million
Book Value
$1.73 per share

Miscellaneous

Free Float
20,808,000
Market Cap
$81.97 million
Optionable
Optionable
Beta
2.81














Second Sight Medical Products Frequently Asked Questions

How has Second Sight Medical Products' stock performed in 2022?

Second Sight Medical Products' stock was trading at $1.63 at the start of the year. Since then, EYES shares have increased by 27.6% and is now trading at $2.08.
View the best growth stocks for 2022 here
.

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products, Inc. (NASDAQ:EYES) issued its quarterly earnings results on Monday, June, 29th. The medical device company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.16.
View Second Sight Medical Products' earnings history
.

Who are Second Sight Medical Products' key executives?

Second Sight Medical Products' management team includes the following people:
  • Mr. Scott Dunbar, Acting Chief Exec. Officer (Age 64, Pay $301.39k)
  • Mr. Edward Jonathon Sedo, Acting Chief Accounting Officer, Principal Financial Officer & Controller (Age 66, Pay $199.18k)
  • Mr. Edward David Randolph, Chief Operating Officer (Age 64, Pay $366.44k)
  • Dr. Jessy Dana Dorn Ph.D., VP of Clinical & Scientific Affairs (Age 46, Pay $282.7k)
  • Gunnar Bjorg, Founder
  • Ms. Lisa M. Wilson, Founder & Pres of In-Site Communications and Investor Relations for Second Sight (Age 57)

What is Will McGuire's approval rating as Second Sight Medical Products' CEO?

5 employees have rated Second Sight Medical Products CEO Will McGuire on Glassdoor.com. Will McGuire has an approval rating of 57% among Second Sight Medical Products' employees. This puts Will McGuire in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Second Sight Medical Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), VBI Vaccines (VBIV), Shopify (SHOP), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), (CGC), Ekso Bionics (EKSO) and OPKO Health (OPK).

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Who are Second Sight Medical Products' major shareholders?

Second Sight Medical Products' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.10%), Renaissance Technologies LLC (0.44%), Simplex Trading LLC (0.00%), Cutler Group LP (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Second Sight Medical Products stock include Gregg Williams and Jonathan Will Mcguire.
View institutional ownership trends for Second Sight Medical Products
.

Which institutional investors are selling Second Sight Medical Products stock?

EYES stock was sold by a variety of institutional investors in the last quarter, including Simplex Trading LLC, and Cutler Group LP.
View insider buying and selling activity for Second Sight Medical Products
or view top insider-selling stocks.

Which institutional investors are buying Second Sight Medical Products stock?

EYES stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Vanguard Group Inc..
View insider buying and selling activity for Second Sight Medical Products
or or view top insider-buying stocks.

How do I buy shares of Second Sight Medical Products?

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Second Sight Medical Products' stock price today?

One share of EYES stock can currently be purchased for approximately $2.08.

How much money does Second Sight Medical Products make?

Second Sight Medical Products (NASDAQ:EYES) has a market capitalization of $81.97 million and generates $3.38 million in revenue each year.

How many employees does Second Sight Medical Products have?

Second Sight Medical Products employs 15 workers across the globe.

How can I contact Second Sight Medical Products?

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The official website for Second Sight Medical Products is www.secondsight.com. The medical device company can be reached via phone at (818) 833-5000, via email at [email protected], or via fax at 818-833-5067.

This page (NASDAQ:EYES) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.